RAC1/miR-3613/RAC1 feedback loop contributes to ovarian cancer progression

Changzhong Li (  15168888909@163.com ) Shandong University A liated Hospital: Shandong Provincial Hospital Ruobing Leng Shandong University A liated Hospital: Shandong Provincial Hospital Yunfang Meng Shandong University A liated Hospital: Shandong Provincial Hospital Na Li Shandong University A liated Hospital: Shandong Provincial Hospital Feifei Li Shandong University A liated Hospital: Shandong Provincial Hospital Yingzi Zhao Shandong University A liated Hospital: Shandong Provincial Hospital

[1]  Gang Yin,et al.  Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10 , 2020, Theranostics.

[2]  E. Chastre,et al.  Rac1 Signaling: From Intestinal Homeostasis to Colorectal Cancer Metastasis , 2020, Cancers.

[3]  T. Hong,et al.  MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer , 2019, Oncogene.

[4]  C. Brakebusch,et al.  Rho GTPases in cancer: friend or foe? , 2019, Oncogene.

[5]  R. Weinberg,et al.  EMT and Cancer: More Than Meets the Eye. , 2019, Developmental cell.

[6]  J. Blenis,et al.  ERK2 regulates epithelial-to-mesenchymal plasticity through DOCK10-dependent Rac1/FoxO1 activation , 2019, Proceedings of the National Academy of Sciences.

[7]  M. Parsons,et al.  In vivo topology converts competition for cell-matrix adhesion into directional migration , 2018, bioRxiv.

[8]  T. Wieland,et al.  Paving the Rho in cancer metastasis: Rho GTPases and beyond. , 2017, Pharmacology & therapeutics.

[9]  E. Christie,et al.  Acquired chemotherapy resistance in ovarian cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Changqing Zhang,et al.  Breast cancer-associated gene 3 interacts with Rac1 and augments NF-κB signaling in vitro, but has no effect on RANKL-induced bone resorption in vivo , 2017, International journal of molecular medicine.

[11]  P. Ottevanger.  Ovarian cancer stem cells more questions than answers. , 2017, Seminars in cancer biology.

[12]  Guo-Lei Zhou,et al.  Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells. , 2017, International journal of oncology.

[13]  A. Mes-Masson,et al.  The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer , 2016, Oncogene.

[14]  F. Tomao,et al.  Bevacizumab in ovarian cancer: A critical review of phase III studies , 2016, Oncotarget.

[15]  Shuang Huang,et al.  Epithelial-Mesenchymal Transition of Ovarian Cancer Cells Is Sustained by Rac1 through Simultaneous Activation of MEK1/2 and Src Signaling Pathways , 2016, Oncogene.

[16]  M. Overduin,et al.  Structural Mechanisms and Drug Discovery Prospects of Rho GTPases , 2016, Cells.

[17]  H. Shen,et al.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin , 2016, Oncogene.

[18]  Ye Chen,et al.  Tumor microenvironment: Sanctuary of the devil. , 2015, Cancer letters.

[19]  L. Hudson,et al.  R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis , 2015, Molecular Cancer Therapeutics.

[20]  M. Pajic,et al.  The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment , 2015, Small GTPases.

[21]  Jun Kuang,et al.  Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome , 2015, Medical Oncology.

[22]  J. George,et al.  Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. , 2014, The Journal of clinical investigation.

[23]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[24]  R. Greil,et al.  Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. , 2014, Blood.

[25]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[26]  P. Hordijk,et al.  Nucleophosmin1 Is a Negative Regulator of the Small GTPase Rac1 , 2013, PloS one.

[27]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[28]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[29]  Ajit Varki,et al.  Molecular basis of metastasis. , 2009, The New England journal of medicine.

[30]  N. Brown.  Cell-cell adhesion via the ECM: integrin genetics in fly and worm. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[31]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[32]  A. Abo,et al.  Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1 , 1991, Nature.